

Kelsey S Lau-Min

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1846787/publications.pdf>

Version: 2024-02-01

8
papers

63
citations

2257833

3
h-index

2053595

5
g-index

8
all docs

8
docs citations

8
times ranked

210
citing authors

#	ARTICLE	IF	CITATIONS
1	Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation. <i>BMC Cancer</i> , 2022, 22, 47.	1.1	16
2	Association between timely targeted treatment and outcomes in patients with metastatic HER2-overexpressing gastroesophageal adenocarcinoma. <i>Cancer</i> , 2022, , .	2.0	0
3	Trends in and determinants of germline <i>BRCA1/2</i> testing in patients with breast and ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10583-10583.	0.8	0
4	Real-world integration of genomic data into the electronic health record: the PennChart Genomics Initiative. <i>Genetics in Medicine</i> , 2021, 23, 603-605.	1.1	29
5	Clinician perspectives on preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 54-54.	0.8	0
6	From Race-Based to Precision Oncology: Leveraging Behavioral Economics and the Electronic Health Record to Advance Health Equity in Cancer Care. <i>JCO Precision Oncology</i> , 2021, 5, 403-407.	1.5	3
7	Adherence to and determinants of guideline-recommended biomarker testing and targeted therapy in patients with gastroesophageal adenocarcinoma: Insights from routine practice. <i>Cancer</i> , 2021, 127, 2562-2570.	2.0	2
8	<i>DPYD</i> and <i>UGT1A1</i> Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation. <i>Pharmacotherapy</i> , 2020, 40, 1108-1129.	1.2	13